共 37 条
Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency
被引:63
作者:
Dvorak, Christopher C.
[1
]
Hassan, Amel
[2
]
Slatter, Mary A.
[3
]
Hoenig, Manfred
[4
]
Lankester, Arjan C.
[5
]
Buckley, Rebecca H.
[6
,7
]
Pulsipher, Michael A.
[8
]
Davis, Jeffrey H.
[9
]
Guengoer, Tayfun
[10
]
Gabriel, Melissa
[11
]
Bleesing, Jacob H.
[12
]
Bunin, Nancy
[13
]
Sedlacek, Petr
[14
]
Connell, James A.
[15
]
Crawford, David F.
[16
]
Notarangelo, Luigi D.
[17
,18
]
Pai, Sung-Yun
[19
,20
]
Hassid, Jake
[1
]
Veys, Paul
[2
]
Gennery, Andrew R.
[3
]
Cowan, Morton J.
[1
]
机构:
[1] Univ Calif San Francisco, Benioff Childrens Hosp, Div Pediat Allergy Immunol & Blood & Marrow Trans, San Francisco, CA 94143 USA
[2] UCL Inst Child Hlth, Mol Immunol Unit, Ctr Immunodeficiency, London, England
[3] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[4] Univ Med Ctr, Dept Pediat, Ulm, Germany
[5] Leiden Univ, Med Ctr, Dept Pediat, NL-2300 RA Leiden, Netherlands
[6] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27706 USA
[7] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27706 USA
[8] Univ Utah, Sch Med, Div Hematol & Hematol Malignancies, Primary Childrens Hosp,Hunstman Canc Inst, Salt Lake City, UT USA
[9] British Columbia Childrens Hosp, Hematol Oncol BMT Program, Vancouver, WA USA
[10] Univ Childrens Hosp, Stem Cell Transplantat Dept, Zurich, Switzerland
[11] Childrens Hosp Westmead, Dept Oncol, Sydney, NSW, Australia
[12] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA
[13] Childrens Hosp Philadelphia, Dept Pediat, Div Oncol, Philadelphia, PA 19104 USA
[14] Teaching Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic
[15] Univ Michigan, Div Pediat Hematol Oncol, Ann Arbor, MI 48109 USA
[16] Univ Oklahoma, Dept Pediat, Oklahoma City, OK USA
[17] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Immunol, Boston, MA USA
[18] Harvard Univ, Sch Med, Childrens Hosp Boston, Manton Ctr Orphan Dis Res, Boston, MA USA
[19] Dana Farber Canc Inst, Boston Childrens Hosp, Div Hematol & Oncol, Boston, MA 02115 USA
[20] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
关键词:
Severe combined immunodeficiency;
hematopoietic cell transplantation;
sibling donors;
unrelated donors;
umbilical cord blood;
conditioning;
serotherapy;
VERSUS-HOST-DISEASE;
BONE-MARROW-TRANSPLANTATION;
COMBINED IMMUNE-DEFICIENCY;
CORD BLOOD;
B-CELLS;
RECONSTITUTION;
CHILDREN;
ENGRAFTMENT;
EXPERIENCE;
CLEARANCE;
D O I:
10.1016/j.jaci.2014.06.021
中图分类号:
R392 [医学免疫学];
学科分类号:
100102 ;
摘要:
Background: Patients with severe combined immunodeficiency disease who have matched sibling donors (MSDs) can proceed to hematopoietic cell transplantation (HCT) without conditioning chemotherapy. Objective: We sought to determine whether the results of HCT without chemotherapy-based conditioning from matched unrelated donors (URDs), either from volunteer adults or umbilical cord blood, are comparable with those from MSDs. Methods: We performed a multicenter survey of severe combined immunodeficiency transplantation centers in North America, Europe, and Australia to compile retrospective data on patients who have undergone unconditioned HCT from either URDs (n = 37) or MSDs (n = 66). Results: Most patients undergoing URD HCT (92%) achieved donor T-cell engraftment compared with 97% for those with MSDs; however, estimated 5-year overall and event-free survival were worse for URD recipients (71% and 60%, respectively) compared with MSD recipients (92% and 89%, respectively; P < .01 for both). URD recipients who received pre-HCT serotherapy had similar 5-year overall survival (100%) to MSD recipients. The incidences of grade II to IV acute and chronic graft-versus-host disease were higher in URD (50% and 39%, respectively) compared with MSD (22% and 5%, respectively) recipients (P < .01 for both). In the surviving patients there was no difference in T-cell reconstitution at the last follow-up between the URD and MSD recipients; however, MSD recipients were more likely to achieve B-cell reconstitution (72% vs 17%, P < .001). Conclusion: Unconditioned URD HCT achieves excellent rates of donor T-cell engraftment similar to that seen in MSD recipients, and reconstitution rates are adequate. However, only a minority will have myeloid and B-cell reconstitution, and attention must be paid to graft-versus-host disease prophylaxis. This approach might be safer in children ineligible for intense regimens to spare the potential complications of chemotherapy.
引用
收藏
页码:935 / U263
页数:24
相关论文